FLAA_CORLD
ID FLAA_CORLD Reviewed; 51 AA.
AC C0XTM5;
DT 25-OCT-2017, integrated into UniProtKB/Swiss-Prot.
DT 26-MAY-2009, sequence version 1.
DT 25-MAY-2022, entry version 34.
DE RecName: Full=Lantibiotic flavucin {ECO:0000305};
DE Flags: Precursor;
GN Name=flaA {ECO:0000305};
GN ORFNames=HMPREF0298_1795 {ECO:0000312|EMBL:EEI16401.1};
OS Corynebacterium lipophiloflavum (strain ATCC 700352 / DSM 44291 / CCUG
OS 37336 / JCM 10383 / DMMZ 1944).
OC Bacteria; Actinobacteria; Corynebacteriales; Corynebacteriaceae;
OC Corynebacterium.
OX NCBI_TaxID=525263;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=ATCC 700352 / DSM 44291 / CCUG 37336 / JCM 10383 / DMMZ 1944;
RA Qin X., Bachman B., Battles P., Bell A., Bess C., Bickham C., Chaboub L.,
RA Chen D., Coyle M., Deiros D.R., Dinh H., Forbes L., Fowler G.,
RA Francisco L., Fu Q., Gubbala S., Hale W., Han Y., Hemphill L.,
RA Highlander S.K., Hirani K., Hogues M., Jackson L., Jakkamsetti A.,
RA Javaid M., Jiang H., Korchina V., Kovar C., Lara F., Lee S., Mata R.,
RA Mathew T., Moen C., Morales K., Munidasa M., Nazareth L., Ngo R.,
RA Nguyen L., Okwuonu G., Ongeri F., Patil S., Petrosino J., Pham C., Pham P.,
RA Pu L.-L., Puazo M., Raj R., Reid J., Rouhana J., Saada N., Shang Y.,
RA Simmons D., Thornton R., Warren J., Weissenberger G., Zhang J., Zhang L.,
RA Zhou C., Zhu D., Muzny D., Worley K., Gibbs R.;
RL Submitted (JAN-2009) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP FUNCTION AS AN ANTIMICROBIAL PEPTIDE, EXPRESSION IN L.LACTIS, MASS
RP SPECTROMETRY, AND ACTIVITY REGULATION.
RC STRAIN=ATCC 700352 / DSM 44291 / CCUG 37336 / JCM 10383 / DMMZ 1944;
RX PubMed=27294279; DOI=10.1021/acssynbio.6b00033;
RA van Heel A.J., Kloosterman T.G., Montalban-Lopez M., Deng J., Plat A.,
RA Baudu B., Hendriks D., Moll G.N., Kuipers O.P.;
RT "Discovery, production and modification of five novel lantibiotics using
RT the promiscuous nisin modification machinery.";
RL ACS Synth. Biol. 5:1146-1154(2016).
CC -!- FUNCTION: Lanthionine-containing peptide antibiotic (lantibiotic)
CC active on certain Gram-positive bacteria. The bactericidal activity of
CC lantibiotics is based on depolarization of energized bacterial
CC cytoplasmic membranes, initiated by the formation of aqueous
CC transmembrane pores (By similarity). Flavucin has high antimicrobial
CC activity against several pathogenic bacteria such as S.aureus,
CC E.faecalis, E.faecium and L.monocytogenes. Is also active against the
CC Gram-negative P.aeruginosa (PubMed:27294279).
CC {ECO:0000250|UniProtKB:P10946, ECO:0000269|PubMed:27294279}.
CC -!- ACTIVITY REGULATION: Antimicrobial activity depends on the dehydration
CC degree and integrity of flavucin. {ECO:0000269|PubMed:27294279}.
CC -!- PTM: Maturation of lantibiotics involves the enzymatic conversion of
CC Thr, and Ser into dehydrated AA and the formation of thioether bonds
CC with cysteine. This is followed by membrane translocation and cleavage
CC of the modified precursor. {ECO:0000250|UniProtKB:P10946}.
CC -!- MISCELLANEOUS: A heterologous expression system was used to produce
CC flavucin. The gene has been fused to the leader peptide gene sequence
CC of the model lantibiotic nisin. The construct was plugged into the
CC nisin expression and modification machinery, and produced in L.lactis.
CC Growth conditions that yield detectable antimicrobial activity in
CC C.lipophiloflavum could not be identified.
CC {ECO:0000269|PubMed:27294279}.
CC -!- SIMILARITY: Belongs to the type A lantibiotic family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; ACHJ01000147; EEI16401.1; -; Genomic_DNA.
DR AlphaFoldDB; C0XTM5; -.
DR SMR; C0XTM5; -.
DR EnsemblBacteria; EEI16401; EEI16401; HMPREF0298_1795.
DR HOGENOM; CLU_211937_0_0_11; -.
DR Proteomes; UP000006196; Unassembled WGS sequence.
DR GO; GO:0005576; C:extracellular region; IEA:InterPro.
DR GO; GO:0005102; F:signaling receptor binding; IEA:UniProtKB-KW.
DR GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR InterPro; IPR006079; Lantibiotic_typ-A_Bacillales.
DR Pfam; PF02052; Gallidermin; 1.
DR TIGRFAMs; TIGR03731; lantibio_gallid; 1.
PE 1: Evidence at protein level;
KW Antibiotic; Antimicrobial; Bacteriocin; Lantibiotic; Thioether bond.
FT PROPEP 1..20
FT /evidence="ECO:0000305|PubMed:27294279"
FT /id="PRO_0000441864"
FT PEPTIDE 21..51
FT /note="Lantibiotic flavucin"
FT /id="PRO_0000441865"
FT CROSSLNK 23..27
FT /note="Lanthionine (Ser-Cys)"
FT /evidence="ECO:0000250|UniProtKB:P10946"
FT CROSSLNK 28..31
FT /note="Beta-methyllanthionine (Thr-Cys)"
FT /evidence="ECO:0000250|UniProtKB:P10946"
FT CROSSLNK 33..38
FT /note="Beta-methyllanthionine (Thr-Cys)"
FT /evidence="ECO:0000250|UniProtKB:P10946"
FT CROSSLNK 42..45
FT /note="Beta-methyllanthionine (Thr-Cys)"
FT /evidence="ECO:0000250|UniProtKB:P10946"
SQ SEQUENCE 51 AA; 5369 MW; 99EC0F39D8E3A714 CRC64;
MSDFTLDFAE GDAADTVSPQ ITSKSLCTPG CITGWMMCNT VTKGCSFTIG K